JAK1 and neoplasm: Importantly, the stable overexpression of Jak1, a key player in tumor cell response to anti-tumor immune attacks29,30,33,34, reversed flavopiridol-induced resistance to IFN and FasL treatments (Supplementary Fig 11C, D).